Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to atopic dermatitis, psoriasis, and hidradenitis suppurativa.
Kaitlyn Bader
Advertisement
Articles by Kaitlyn Bader
FDA action is no longer expected in Q3 of 2023.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD
5